Infectious disease
The COVID-19 pandemic has seen a full-blown effort from biopharma and researchers to develop new drugs and test old ones against the disease, with highly mixed results.
Antiviral pills against COVID-19 show promise for treating the disease, but they are not broadly accessible yet.
The same advantage against HIV-1 possessed by a person with the inactive CCR5 variant potentially doubles as resistance to any virus that capitalizes on or manipulates that receptor.
Business with customers in the pharma and biotech sector was a key revenue driver, said Thermo Fisher CEO Marc Casper, adding that this business grew by 25% over the year.
COVID-19 is a respiratory illness and presents many other symptoms, including blood clots. For more details and other COVID-19 news, continue reading.
COVID-19 causes certain conditions or is being implicated in their earlier onset. Type 1 diabetes and Parkinson’s disease are prime examples. According to researchers, it also may cause fetal inflammation.
For 2021, with $6.19 billion in sales the monoclonal antibody counted for a little less than one-third of Regeneron’s overall $16.07 billion revenue.
FDA Action Alert for February 7
The Omicron surge appears to be waning in the U.S., but a subvariant of Omicron seems to be surging in other countries where the Omicron surge faded.
Finally, Pfizer has submitted the request to FDA to grant emergency use status to their vaccine for children. Here’s everything you should know about the vaccine.
PRESS RELEASES